Page last updated: 2024-09-03

gefitinib and dihydrotestosterone

gefitinib has been researched along with dihydrotestosterone in 2 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(dihydrotestosterone)
Trials
(dihydrotestosterone)
Recent Studies (post-2010) (dihydrotestosterone)
5,2315662,9199,3253071,517

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)dihydrotestosterone (IC50)
Plasma kallikreinHomo sapiens (human)0.0031
Glucocorticoid receptorHomo sapiens (human)0.54
Sex hormone-binding globulinHomo sapiens (human)0.0038
Progesterone receptorOryctolagus cuniculus (rabbit)0.44
Progesterone receptorHomo sapiens (human)7.3
Mineralocorticoid receptor Homo sapiens (human)0.36
Sex hormone-binding globulinRattus norvegicus (Norway rat)0.023
Androgen receptorHomo sapiens (human)0.0048
Androgen receptorRattus norvegicus (Norway rat)0.4041
Androgen receptorMus musculus (house mouse)0.001
Mineralocorticoid receptorRattus norvegicus (Norway rat)2.1
Testosterone 17-beta-dehydrogenase 3Homo sapiens (human)0.0026

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C1
Earp, HS; Gregory, CW; Liu, Y; Majumder, S; McCall, W; Mohler, JL; Sartor, CI; Whang, YE1

Other Studies

2 other study(ies) available for gefitinib and dihydrotestosterone

ArticleYear
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
    International journal of cancer, 2005, Jul-01, Volume: 115, Issue:4

    Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous

2005
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
    Cancer research, 2005, Apr-15, Volume: 65, Issue:8

    Topics: Acetylation; Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; Dihydrotestosterone; ErbB Receptors; Gefitinib; Histones; Humans; Immunoglobulin Fragments; Lapatinib; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Response Elements; Transcription, Genetic

2005
chemdatabank.com